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Lung cancer has entered the era of personalized therapy with histologic subclassification
and the presence of molecular biomarkers becoming increasingly important in therapeutic
algorithms. At the same time, biopsy specimens are becoming increasingly smaller as diag-
nostic algorithms seek to establish diagnosis and stage with the least invasive techniques.
Here, we review techniques used in the diagnosis of lung cancer including bronchoscopy,
ultrasound-guided bronchoscopy, transthoracic needle biopsy, and thoracoscopy. In addi-
tion to discussing indications and complications, we focus our discussion on diagnostic
yields and the feasibility of testing for molecular biomarkers such as epidermal growth fac-
tor receptor and anaplastic lymphoma kinase, emphasizing the importance of a sufficient
tumor biopsy.
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INTRODUCTION
Lung cancer remains the leading cause of cancer death in North
America. In Canada, an estimated 25,500 Canadians will be diag-
nosed with lung cancer in 2014 (1). The majority of these will be
non-small cell lung cancer (NSCLC) and unresectable.
At diagnosis, 75% of lung cancer patients will have either locally
advanced or metastatic disease (2). The goal in this group of
patients is to establish the diagnosis and, ideally, confirm stag-
ing with the least invasive technique possible. As a result of this
approach, biopsy specimens are becoming increasingly smaller. Up
to 80% of patients receiving chemotherapy for advanced disease
will have only a small biopsy and/or cytology samples available for
diagnosis (3).
The adequacy of these samples has important ramifications.
Lung cancer has entered an era of personalized therapy with
treatment based on histologic subtypes (adenocarcinoma ver-
sus squamous) and the presence of molecular markers [epider-
mal growth factor receptor (EGFR) and anaplastic lymphoma
kinase (ALK)]. For instance, several trials have demonstrated that
response rate and overall survival is significantly better with peme-
trexed in patients with non-squamous histology compared with
patients with squamous histology (4). Trials using tyrosine kinase
inhibitors (TKIs) have observed that patients with NSCLC tumors
harboring EGFR mutations derive a greater benefit from treat-
ment with TKIs than wild-type tumors (5). In fact, a number of
trials have consistently shown a statistically significant and clin-
ically meaningful benefit of TKIs over standard chemotherapy
in mutation positive patients (5–7). The ALK inhibitor, crizo-
tinib, is effective in patients with NSCLC harboring the ALK
rearrangement (8).
Procurement of adequate tissue samples that allow for accurate
characterization of histology and molecular testing is essential.
A multidisciplinary approach is recommended. Physicians who
obtain tissue samples (respirologists, interventional radiologists,
and thoracic surgeons) need to be aware of the tissue yields of their
procedures. Likewise, pathologists need to communicate the tissue
yields and to be judicious in tissue use especially when managing
small biopsy and cytology specimens. Finally, medical oncologists
should be aware of when to ask for more tissue in patients in whom
the treatment plan will be significantly impacted by further char-
acterization. Medical oncologist may recommend that a patient
with a known lung cancer be rebiopsied or that a metastatic site be
biopsied in addition to the primary site in order to clarify the mole-
cular status of the tumor. This can provide important information
with regard to treatment options or as to why therapies fail.
In this article, techniques used in the diagnosis of lung can-
cer will be discussed including the expected tissue yields and the
feasibility of histologic characterization and molecular testing.
DIAGNOSIS OF LUNG CANCER
RAPID ASSESSMENT CLINICS
Lung cancer guidelines recommend prompt investigation and
referral for treatment (9).
Recently, rapid access clinics have been developed to reduce wait
times and initiate investigations based on established algorithms
to provide the most information about diagnosis and staging with
the least risk to the patient. Bronchoscopy with or without lymph
node sampling is frequently recommended as the initial diagnostic
procedure.
FIBEROPTIC BRONCHOSCOPY
The bronchoscope is one of the primary diagnostic tools in
lung cancer. Flexible bronchoscopy, usually performed under
local anesthesia and with minimal sedation, provides a thorough
examination of all segmental bronchi within minutes. Compli-
cations for this procedure are rare, with major complication rates
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between 0.08 and 5% (10). Complications include pneumothorax,
hypoxemia, and hemorrhage (11).
Endobronchial tumor may be visible as an exophytic mass
or submucosal infiltration (Figure 1A). The diagnostic yield for
endobronchial biopsy when a lesion is visible is 70–90% (12). Five
biopsy specimens have been shown to be optimal for achieving
a diagnostic yield in central lesions (13). Combining the results
of bronchial biopsy, bronchial brushing, and bronchial washing
increases tissue yields (14), and it is better to do brushing after
biopsy (15).
Biopsy specimens are, in general, small averaging about 300 cells
in aggregate. Bronchial lavage yields the least number of malig-
nant cells. In biopsy specimens, the percentage (%) of tumor cells
can be relatively low. Coghlin et al. found the mean % of area of
tumor in an endobronchial sample to be 33%. In fewer than half of
their cases (48%), tumor was found in all biopsy specimens (16).
Although five specimens may be enough to establish the diagno-
sis of lung cancer, the number of specimens required to provide
detailed sub classification and molecular analysis has not be estab-
lished. In one series, EGFR testing could be performed in 100%
of endobronchial biopsy specimens that established a diagnosis of
lung cancer (17).
Endobronchial cryobiopsies could be one evidence-based way
of achieving a higher diagnostic yield and a higher molecular
analysis potential. Compared with conventional bronchoscopic
biopsies, cryobiopsies result in an increase in biopsy sample size
and yield (18, 19).
In the case of more peripheral lesions, when the endobronchial
exam is normal, the diagnostic yield falls to 40% (20, 21). The diag-
nostic yield can be increased when computed tomography (CT)
FIGURE 1 | (A) Endobronchial tumor visible in an airway. (B) Ultrasound
image of a peripheral lung cancer as visualized by radial EBUS-GS. The clear
central area is the ultrasound probe in the airway. The surrounding isoechoic
shadow represents a tumor. The hyperechoic line surrounding the tumor is an
ultrasound phenomenon produced by the sudden change in tissue density
from tumor to aerated lung. (C) Mediastinal lymph node station accessibility
by EBUS, mediastinoscopy, and EUS. (D) Real-time needle aspiration of a
lymph node. The needle (hyperechoic line coming from the top left corner of
the screen) is penetrating the lymph node under direct ultrasound
visualization.
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images are available for review prior to bronchoscopy (22). This
allows the bronchoscopist to better localize the bronchial segment
containing tumor. When positive, the diagnoses in these cases are
usually made on the basis of cytology: bronchial brushings or
washings. Molecular markers can be performed on these cytologi-
cal specimens with varying degrees of success. One series, however,
found that in the case of bronchial lavage, more than half of the
cytological specimens that confirmed the diagnosis of lung cancer
could not be used for molecular testing (23).
Ultrasonography using a guide sheath (radial EBUS-GS) and
electromagnetic navigation (ENB) can provide transbronchial
biopsy specimens, improving the possibility of having adequate
tissue for molecular analysis. In the case of a peripheral lesion
where the endobronchial exam is negative and radial EBUS-GS
or ENB are not available, consideration should be given to other
diagnostic procedures such as transthoracic needle aspirate.
RADIAL EBUS
Endobronchial ultrasonography using a sheath guide (EBUS-GS)
can increase the diagnostic yield of peripheral lung lesions. For
lesions less than 2 cm, the diagnostic yield can increase from 36%
using conventional bronchoscopy to between 58 and 70% (24).
This technique allows for visualization of the lesion (Figure 1B)
and repeated access to the lesion by brush, forceps biopsy, and
bronchial wash. The resulting specimens are cytological and small
biopsies.
Recently, ENB and virtual bronchoscopic navigation system
(VBNS) have been developed to assist the diagnosis of periph-
eral lung lesions in conjunction with EBUS-GS. Using ENB, yields
in peripheral lesions can be further improved upon. Combining
radial EBUS and ENB resulted, in one series, in a diagnostic yield
approaching 90% compared with 69% for radial EBUS alone (25).
No EMN complications have been reported. VBNS has also been
used with EBUS-GS with an overall diagnostic yield ranging from
63.3 to 84.4%, and in lesions less than 2 cm in diameter, rang-
ing from 44 to 75.9% (26). VBNS increases diagnostic yield and
decreases procedure time (27). Presently, there is little data on the
yield of molecular testing on specimens obtained by EBUS-GS
or ENB/VBNS. Tsai et al. performed EBUS-guided brushings in
122 patients with peripheral lung cancer receiving flexible bron-
choscopy. The yield for tumor cells was 68.9%. Genotyping of
EGFR and KRAS was successfully implemented in 80 (95.2%) of
the 84 cytology-proven brushing samples (28). It is probable that
the yields are similar to conventional bronchoscopy as the speci-
mens obtained are small biopsies and bronchial brushing/lavage
cytology.
EBUS TRANSBRONCHIAL NEEDLE ASPIRATION
Endobronchial ultrasound-guided transbronchial needle aspira-
tion (EBUS-TBNA) is a minimally invasive technique with a high
diagnostic yield for mediastinal lymph node staging of lung cancer
patients. Accurate staging is an essential step in the investiga-
tion of lung cancer patients. EBUS-TBNA is particularly useful
as diagnosis and staging can be achieved with a single procedure.
The technique is performed using a dedicated flexible bron-
choscope with an integrated ultrasound transducer. It allows for
sampling of mediastinal and hilar lymph nodes under direct vision
using local anesthesia and moderate sedation. The upper and
lower paratracheal, prevascular, subcarinal, and hilar lymph node
stations can all be sampled using this technique (Figure 1C).
A similar technique using a gastroscope with an integrated
ultrasound probe (EUS) can also sample mediastinal lymph nodes.
Nodal stations that can be accessed with EUS include aortopul-
monary window, subcarinal, para-esophageal, and pulmonary
ligament.
Herth et al. assessed EBUS yields in 502 patients with sus-
pected lung cancer, comparing EBUS-TBNA results with operative
findings (29). The reported sensitivity was 94% and specificity
was 100%. Several studies have compared EBUS-TBNA to medi-
astinoscopy and found both techniques to have comparable results
for mediastinal staging (30, 31). EBUS-TBNA has some advantages
over mediastinoscopy, in that EBUS-TBNA can be used to restage
a patient post surgery or radiation therapy, where a repeat medi-
astinoscopy would prove difficult because of fibrotic changes (32).
Additionally, it can be performed in high-risk patients with several
comorbidities such as COPD (33).
Tissue samples by EBUS-TBNA are typically small cytology
samples obtained using a dedicated 22 gage needle (Figure 1D).
Some institutions use rapid on-site evaluation (ROSE) of aspirated
samples by a cytopathologist. One of the main advantages of ROSE
is reduction of the number of passes and stations sampled, and
avoidance of other biopsy techniques like transbronchial biopsy.
Lee and colleagues have demonstrated that maximum diagnostic
values for achieving a diagnosis of lung cancer are achieved with
three aspirations per node when ROSE is not available (34). Mol-
ecular testing for EGFR and ALK mutations can be successfully
performed on EBUS-TBNA specimens. In several series, using
ROSE, molecular testing can be performed in between 70 and
90% of EBUS-TBNA samples (35–37). Yarmus et al. found that a
median of four passes in the presence of ROSE provided an ade-
quate amount of tissue for molecular analysis in 95% of patients
studied (38). In the absence of ROSE, Navasakulpong and col-
leagues found that 93% of EBUS-TBNA specimens from a single
lymph node station were adequate for EGFR testing with an aver-
age of 3.5 passes per lymph node. The minimum tumor cell count
that allowed for successful EGFR testing in this series was 100
cells (39). Schmid-Bindert et al. found that EBUS-TBNA pro-
vided the highest yield for biomarker testing when compared to
bronchoscopic forceps biopsy and CT-guided core biopsy (17).
Questions that remain to be answered are whether a larger nee-
dle (21 gage) results in better yields, whether mixing tissue from
more than one lymph node station, once staging is established,
can improve the yield of molecular testing, and finally, whether
combining EBUS and EUS increases tissue yields for molecular
analysis.
MEDIASTINOSCOPY
Cervical mediastinoscopy is used predominantly in the staging
of lung cancer. It is performed by a thoracic surgeon under gen-
eral anesthesia in an operating room. A small incision is made at
the base of the neck and a mediastinoscope is introduced. The
sensitivity of mediastinoscopy for detecting cancer in mediasti-
nal lymph nodes is between 80 and 95% (32, 40). False neg-
ative rates vary between 5 and 9% and are attributed to the
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inability to access para-esophageal, inferior pulmonary ligament,
and aortopulmonary nodes.
Tissue samples vary from millimeters to centimeters depending
on the size of the nodes biopsied. Tissue samples are sufficient for
molecular testing. The complication rate is between 2 and 5% and
includes hoarseness, infection, and bleeding (41).
Several series have compared EBUS to mediastinoscopy (42).
Both modalities have comparable sensitivities in staging the medi-
astinum. Mediastinoscopy has the advantage of larger tissue sam-
ples, compared with EBUS. It is unclear if this translates into better
molecular subtyping as little comparative data exist. The disad-
vantage of mediastinoscopy is the need for general anesthesia and
OR time.
TRANSTHORACIC NEEDLE ASPIRATE
A total of 10–20% of cases of NSCLC will present as a solitary pul-
monary nodule. In patients who are not candidates for surgery
or in patients who have advanced disease in whom the most
accessible site for biopsy is a peripheral lung nodule, transtho-
racic needle aspiration (TTNA) and biopsy (TTNB) are useful
diagnostic procedures.
Transthoracic needle aspiration can be performed under CT or
fluoroscopic guidance. CT-guided aspiration and biopsies result
in a higher diagnostic yield compared to fluoroscopy (43).The
most commonly used technique is a coaxial system, in which a
larger gage needle is inserted into the edge of the lesion and a
smaller needle is passed through the larger one. This allows for
a single pleural puncture and repeat needle passes by the smaller
needle reducing the risk of complications. Major complications
are bleeding and pneumothorax and occur in 10% and up to 20%
of cases, respectively (44). Contraindications to TTNA are pre-
vious pneumonectomy, severe chronic obstructive lung disease,
especially with bullous formation, mechanical ventilation, lesions
too close to vascular structures, and high risk for bleeding (45).
Transthoracic needle aspiration has a diagnostic accuracy of
between 80 and 95% for lung cancer (46, 47). Specimens obtained
by TTNA are cutting-needle core biopsies and needle aspirate
cytology. Core-needle biopsy specimens usually contain enough
cellular material for pathologic subtyping and molecular analy-
sis. The average number of cells obtained by CT-guided needle
biopsy is 500 cells per biopsy (48). Zhuang et al. showed that
CT-guided TTNA/TTNB performed using an 18 or 20 gage could
obtain tumor samples ranging from 0.5 to 1.5 cm in length and
that these samples were 100% adequate for histological and EGFR
mutation analysis (49). In addition, Fassina et al. showed that
TTNA samples can be used for EGFR and KRAS mutation analy-
sis (50). da Cunha Santos et al. found that in a review of 602 fine
needle aspirates, histological subtyping agreement with resected
specimens was achieved in 93% of cases (51).
PLEURAL FLUID ANALYSIS AND MEDICAL THORACOSCOPY
In rapid diagnostic clinics for the evaluation of suspected lung
cancer, diagnostic procedures that allow for simultaneous staging
and diagnosis are preferred. In patients with suspected lung can-
cer presenting with an accessible pleural effusion, thoracentesis
is recommended to distinguish between a malignant versus para-
pneumonic effusion (21). The yield of pleural fluid cytology is
60–80% with repeat sampling (52, 53). Use of cell block methods
improves the diagnostic utility of pleural cytology compared with
conventional smear cytology by providing higher cellularity and
better morphological features to allow for pathologic subtyping.
Using cell blocks of pleural fluid, molecular testing for EGFR and
KRAS has been performed with an insufficiency rate of 3.7% (1 in
27 specimens) (54).
Medical thoracoscopy is recommended when cytology speci-
mens are non-diagnostic or insufficient for histologic classifica-
tion. It offers higher yield compared with Abrams needle and
CT-guided pleural biopsy in malignant pleural disease (55). In
addition to being able to directly visualize and biopsy nodules on
the parietal pleural surface, thoracoscopy allows for drainage of
pleural fluid and talc pleurodesis in the case of malignant effusions.
Medical thoracoscopy can be performed in a dedicated sterile
endoscopy suite under local anesthesia and conscious sedation.
A pneumothorax is artificially induced, and a rigid thoracoscope
is introduced into the pleural cavity. Under direct vision, parietal
pleural nodules can be biopsied. The diagnostic yield of medical
thoracoscopy for malignancy is 93–97% (56). Biopsy specimens
are typically about 5 mm and multiple specimens can be obtained
during the procedure. The size of these specimens is adequate
for pathological subtyping, and molecular analysis was possible in
100% of specimens tested in one series (57).
Medical thoracoscopy is a relatively safe procedure with a
complication rate of 1.9% (58). Persistent air leak, subcutaneous
emphysema, and fever are the most common complications. Mor-
tality is rare with 1 death reported in more than 8000 cases (53).
TISSUE STRATEGIES FOR PATHOLOGICAL SUBTYPING AND
MOLECULAR ANALYSIS
Strategies have been proposed to allow for subtyping of NSCLC
and testing of molecular markers in small biopsy and cytol-
ogy specimens (59). With any specimen, the first approach is to
establish squamous or adenocarcinoma differentiation based on
morphology under light microscopy. The typical features of ade-
nocarcinoma include glandular differentiation of cell clusters and
in individual cells, the presence of basophilic cytoplasm, eccentric
nuclei, and a single macronucleolus. Squamous differentiation is
characterized by keratinization, intercellular bridges, and keratin
pearls in small biopsies. Individual cells may have long cytoplas-
mic tails, central nuclei, dense chromatin, and poorly developed
nucleoli.
In cases of NSCLC that cannot be subtyped based on mor-
phology, immunohistochemistry (IHC) is used. Because of the
small amounts of tissue, IHC should be used judiciously. It is rec-
ommended to use one adenocarcinoma marker (TTF1) and one
squamous marker (p63 or CK 5/7) to attempt to further subtype
NSCLC (60).
In the case of adenocarcinoma, molecular markers can then be
performed. Currently, EGFR and ALK are performed, but other
markers such as ROS1 and KRAS may also be considered. In
tumors that cannot be subtyped based on morphology and IHC,
a designation of NSCLC not otherwise specified (NOS) is made.
Decisions can be made whether additional tissue is warranted;
however, recommendations for EGFR testing include specimens
designated as NSCLC-NOS (61).
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Table 1 |Yields of various procedures used to diagnose lung cancer.
Diagnostic modality Specimen types Diagnostic yield Adequacy for biomarker testing
Bronchoscopy Endobronchial biopsy 70–90% (if lesion visible) Up to 100% in one series for endobronchial biopsy.
Less than 50% in washingsBrushing cytology Yields improve when biopsy,
brushing, and washing combinedWashing cytology
Radial EBUS-GS Transbronchial biopsy 58–70% when biopsy, brushing,
and washings combined
71% in one series examining bronchial brushing
For peripheral lesions
2 cm or less
Brushing cytology
Washing cytology
EBUS-TBNA Needle aspirate cytology Up to 94% 70–95%
Mediastinoscopy Biopsy 80–95% Not well established, but likely adequate based on size
CT-guided TTNA Core-needle biopsy 80–95% 100% in one series
Needle aspirate
Thoracentesis Fluid cytology 60–80% Insufficiency rate of 3.7% in one series
Medical thoracoscopy Biopsy 93–97% 100% in one series
The minimum number of malignant tumor cells required for
molecular marker testing has not been well established. In gen-
eral, larger samples with at least 200–400 malignant cells are
preferred (62).
Communication among the multiple physicians involved in
the care of patients with lung cancer must take into considera-
tion issues of tissue procurement strategies in order to optimize
diagnostic yield and molecular characterization of tumors. Only a
multidisciplinary approach can ensure that the needs of the med-
ical oncologist for treatment planning are reflected into judicious
tissue procurement, clinical staging, and thoughtful tissue analy-
sis. Moreover, local institutional strategies must be implemented to
take into consideration the local availability of different diagnostic
modalities and molecular analyses. Solutions regarding issues of
cost-effectiveness and quality control must be individualized for
each center, and ongoing monitoring is important to ensure that
safe and efficient diagnostic services are delivered. This is especially
important given that many of the above-mentioned technologies
have mostly been studied only in highly specialized centers.
SUMMARY AND RECOMMENDATIONS
A sufficient tumor biopsy is essential in the diagnosis of lung cancer
in order to subtype NSCLC and to establish the presence molecular
markers. Important therapeutic decisions are made on the basis of
these specimens. In this article, we have summarized the various
techniques used in the diagnosis of lung cancer and their respec-
tive yields in terms of tissue, pathological subtype, and molecular
testing. Table 1 summarizes the diagnostic yields of specimens
obtained.
A multidisciplinary approach in establishing a diagnosis of lung
cancer is strongly recommended to optimize tissue yields and ulti-
mately patient outcomes. In general, the least invasive procedure
should be favored and biopsy specimens favored over cytology
specimens. There is, however, increasing evidence to suggest that,
when handled judiciously, cytology specimens can prove to be
sufficient for diagnosis and molecular analysis. Understanding
the yields of diagnostic procedures is essential in diagnosing and
treating lung cancer in an era of personalized therapy.
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